Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report

Immune checkpoint inhibitors (ICIs) have achieved prominent efficacy in the treatment of numerous cancers, which is the most significant breakthrough in cancer therapy in recent years. However, ICIs are associated with a series of immune‐related adverse events (irAEs). Pneumonitis is an uncommon but...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yi‐hui, Zhou, Yang, Liu, Yuan‐yuan, Zhang, Guang‐ju, Xiao, Lei, Li, Na, Qin, Hai‐feng, Wang, Jian‐gong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169295/
https://www.ncbi.nlm.nih.gov/pubmed/33949137
http://dx.doi.org/10.1111/1759-7714.13967
_version_ 1783702029013614592
author Li, Yi‐hui
Zhou, Yang
Liu, Yuan‐yuan
Zhang, Guang‐ju
Xiao, Lei
Li, Na
Qin, Hai‐feng
Wang, Jian‐gong
Zhang, Li
author_facet Li, Yi‐hui
Zhou, Yang
Liu, Yuan‐yuan
Zhang, Guang‐ju
Xiao, Lei
Li, Na
Qin, Hai‐feng
Wang, Jian‐gong
Zhang, Li
author_sort Li, Yi‐hui
collection PubMed
description Immune checkpoint inhibitors (ICIs) have achieved prominent efficacy in the treatment of numerous cancers, which is the most significant breakthrough in cancer therapy in recent years. However, ICIs are associated with a series of immune‐related adverse events (irAEs). Pneumonitis is an uncommon but potentially fatal irAE. In the case reported here, a patient with advanced small cell lung cancer (SCLC) had rapid progression of disease following chemotherapy and received ICIs. The patient experienced severe immune‐related hyperthermia followed by immune‐related pneumonitis. Fortunately, a good clinical response was achieved after the patient received corticosteroids and tocilizumab.
format Online
Article
Text
id pubmed-8169295
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-81692952021-06-05 Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report Li, Yi‐hui Zhou, Yang Liu, Yuan‐yuan Zhang, Guang‐ju Xiao, Lei Li, Na Qin, Hai‐feng Wang, Jian‐gong Zhang, Li Thorac Cancer Case Reports Immune checkpoint inhibitors (ICIs) have achieved prominent efficacy in the treatment of numerous cancers, which is the most significant breakthrough in cancer therapy in recent years. However, ICIs are associated with a series of immune‐related adverse events (irAEs). Pneumonitis is an uncommon but potentially fatal irAE. In the case reported here, a patient with advanced small cell lung cancer (SCLC) had rapid progression of disease following chemotherapy and received ICIs. The patient experienced severe immune‐related hyperthermia followed by immune‐related pneumonitis. Fortunately, a good clinical response was achieved after the patient received corticosteroids and tocilizumab. John Wiley & Sons Australia, Ltd 2021-05-05 2021-06 /pmc/articles/PMC8169295/ /pubmed/33949137 http://dx.doi.org/10.1111/1759-7714.13967 Text en © 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Li, Yi‐hui
Zhou, Yang
Liu, Yuan‐yuan
Zhang, Guang‐ju
Xiao, Lei
Li, Na
Qin, Hai‐feng
Wang, Jian‐gong
Zhang, Li
Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
title Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
title_full Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
title_fullStr Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
title_full_unstemmed Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
title_short Severe immune‐related hyperthermia followed by immune‐related pneumonitis with PD‐1 inhibitor (sintilimab) in small cell lung cancer: A case report
title_sort severe immune‐related hyperthermia followed by immune‐related pneumonitis with pd‐1 inhibitor (sintilimab) in small cell lung cancer: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169295/
https://www.ncbi.nlm.nih.gov/pubmed/33949137
http://dx.doi.org/10.1111/1759-7714.13967
work_keys_str_mv AT liyihui severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport
AT zhouyang severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport
AT liuyuanyuan severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport
AT zhangguangju severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport
AT xiaolei severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport
AT lina severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport
AT qinhaifeng severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport
AT wangjiangong severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport
AT zhangli severeimmunerelatedhyperthermiafollowedbyimmunerelatedpneumonitiswithpd1inhibitorsintilimabinsmallcelllungcanceracasereport

Ejemplares similares